Daniel Barocas
Overview
Explore the profile of Daniel Barocas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaeffer E, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al.
J Natl Compr Canc Netw
. 2023 Oct;
21(10):1067-1096.
PMID: 37856213
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment...
2.
Wei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al.
J Urol
. 2023 Apr;
210(1):46-53.
PMID: 37096582
Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy,...
3.
Wei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al.
J Urol
. 2023 Apr;
210(1):54-63.
PMID: 37096575
Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy,...
4.
Schaeffer E, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al.
J Natl Compr Canc Netw
. 2022 Dec;
20(12):1288-1298.
PMID: 36509074
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate...
5.
Morgan S, Hoffman K, Loblaw D, Buyyounouski M, Patton C, Barocas D, et al.
J Urol
. 2019 Feb;
201(3):528-534.
PMID: 30759696
Purpose: The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate...
6.
Morgan S, Hoffman K, Loblaw D, Buyyounouski M, Patton C, Barocas D, et al.
Pract Radiat Oncol
. 2018 Oct;
8(6):354-360.
PMID: 30322661
Purpose: The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate...
7.
Morgan S, Hoffman K, Loblaw D, Buyyounouski M, Patton C, Barocas D, et al.
J Clin Oncol
. 2018 Oct;
:JCO1801097.
PMID: 30307776
No abstract available.
8.
Tyson M, Arora S, Scarpato K, Barocas D
Urol Oncol
. 2016 Apr;
34(7):326-32.
PMID: 27083114
The advent of multiparametric magnetic resonance imaging (MRI) has ushered in a new era for urologists who perform prostate needle biopsies. The fusion of MRI with transrectal ultrasound (US) allows...
9.
Anderson C, Weber R, Patel D, Lowrance W, Mellis A, Cookson M, et al.
J Urol
. 2016 Apr;
196(4):1014-20.
PMID: 27044571
Purpose: Previous studies have demonstrated significant variation in recurrence rates after transurethral resection of bladder tumor, likely due to differences in surgical quality. We sought to create a framework to...
10.
Lee C, Barocas D, Globe D, Oefelein M, Colayco D, Bruno A, et al.
J Urol
. 2012 Oct;
188(6):2114-9.
PMID: 23083857
Purpose: Perioperative intravesical chemotherapy following transurethral resection of bladder tumor has been underused despite level 1 evidence supporting its performance. The primary objective of this study was to estimate the...